Pepaxti

melphalan flufenamide

Table of contents

Opinion

On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pepaxti1, intended for the treatment of multiple myeloma. The applicant for this medicinal product is Oncopeptides AB.

Pepaxti will be available as a 20 mg powder for concentrate for solution for infusion. The active substance of Pepaxti is melphalan flufenamide, an antineoplastic agent (ATC code: L01AA10). Melphalan flufenamide is a lipophilic derivative of melphalan designed to enhance cell penetration. Once inside the cells, melphalan inhibits DNA and RNA synthesis, causing tumour cell death.

The benefit of Pepaxti is its ability to bring about a response in patients with relapsed and refractory multiple myeloma. The most common side effects are thrombocytopenia, neutropenia and anaemia.

The full indication is:

Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Pepaxti should be prescribed by physicians experienced in the treatment of multiple myeloma.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.


1 This product was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained

Key facts

Name
Pepaxti
Agency product number
EMEA/H/C/005681
International non-proprietary name (INN) or common name
  • melphalan flufenamide
Active substance
  • Melphalan flufenamide hydrochloride
Therapeutic area
Multiple Myeloma
Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Date opinion adopted
23/06/2022
Company name
Oncopeptides AB
Status
Positive
Application type
Initial authorisation

Related content

How useful was this page?

Add your rating